U.S. says two Indian nationals indicted in counterfeit Ozempic smuggling scheme

Between July 2023 and April 2024, Swapnadip Roy and Vicky Ramancha allegedly obtained counterfeit Ozempic in China and sold it to U.S. distributors at discounted prices, Justice Department said

A U.S. federal grand jury has indicted two Indian nationals for ​allegedly smuggling and selling counterfeit ⁠Ozempic, the weight-loss drug, the Department of Justice said on Tuesday (September 29, 2026). One of the defendants, ‌Swapnadip Roy, pleaded not guilty after being extradited from Italy ‌, while the other, Vicky Ramancha, ‌remains ⁠at large, the department said.

Between ⁠July 2023 and April 2024, Mr. Roy and Mr. Ramancha allegedly obtained counterfeit Ozempic in China ​and sold it ‌to U.S. distributors at discounted prices, it said.

A legal representative for Mr. Roy did not immediately respond to ‌a request for comment. One ​for Mr. Ramancha was not immediately available.

The counterfeit medication included packaging, ⁠inserts, and labels allegedly meant to convince purchasers that they were receiving authentic ‌Ozempic, the popular weight-loss drug that can cost hundreds of dollars per month for patients. “The scheme continued even after the FDA seized some of the counterfeit Ozempic in ‌December 2023 and issued a public ​warning regarding the products,” the Justice Department said.

Mr. Roy and Mr. Ramancha ⁠were charged with smuggling and selling counterfeit drugs, conspiracy to commit smuggling and to defraud the United States. ‌They face up to 71 years in prison if convicted.

  • Related Posts

    Mankind Pharma to Acquire 70% Stake in Belgium’s ACTx

    Shares of Mankind Pharma fell more than 2% on 16 October after the company announced that it has signed an agreement to acquire a 70% stake in Belgium-based biotechnology company…

    Can a drug licence be suspended before a hearing? Karnataka HC explains rule

    NEW DELHI: Can a drug licensing authority suspend a pharmaceutical distributor’s licence while issuing a show-cause notice, before considering its response? The Karnataka high court has said the procedure under…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Mankind Pharma to Acquire 70% Stake in Belgium’s ACTx

    Mankind Pharma to Acquire 70% Stake in Belgium’s ACTx

    Can a drug licence be suspended before a hearing? Karnataka HC explains rule

    Can a drug licence be suspended before a hearing? Karnataka HC explains rule

    A Boy survives 18th Floor Fall, thanks to Yashoda Medicity

    A Boy survives 18th Floor Fall, thanks to Yashoda Medicity

    AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

    AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

    FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

    FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

    Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

    Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs